MediWound (NASDAQ:MDWD) reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs.
On the company’s earnings call, Chief Executive Officer Ofer G
MediWound's Q3 2025 results show revenue miss but a smaller-than-expected loss. The company advances its EscharEx pipeline and expands NexoBrid manufacturing.
MediWound's Q2 2025 results show mixed performance: $5.7M revenue (+43% QoQ) missed estimates, but shares rose 5% on NexoBrid growth and EscharEx progress.
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family
Shares of Sharps Technology, Inc. (NASDAQ:STSS) rose sharply in today's pre-market trading after the company announced it received two purchase orders for a total of approximately one million SecureGard syringes for 2024 delivery.
